Walk into your consultation informed. These 12 questions cover candidacy, drug selection, dosing, monitoring, insurance, and exit strategy — plus what a good answer actually sounds like for each one.
Why This Matters: GLP-1 therapy is a significant medical commitment. The best outcomes happen when patients are informed partners in their care — not passive recipients of a prescription. These 12 questions are designed to help you get a complete, honest picture of what you're starting, why, and how you'll manage it over time.
Bring this list — or a printout of it — to your initial consultation. You don't need to ask every question verbatim. The goal is to walk out of that appointment with answers. A provider who can't (or won't) address these questions substantively is a provider you should think twice about.
In the telehealth context, which is how most people access compounded GLP-1 medications in March 2026, you may be communicating through a patient portal, messaging system, or video call. These questions work in all of those formats. If you don't get clear answers to the most important ones, follow up. You're entitled to understand your own treatment.
This seems obvious, but it's worth asking explicitly. FDA-approved indications for GLP-1 weight management require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease). Off-label use exists but should be discussed openly.
You also want to know if anything in your medical history is a red flag — thyroid history, pancreatitis history, eating disorder history, pregnancy status, or medications that could interact.
Your provider confirms you meet BMI criteria, reviews your relevant medical history, and explicitly addresses any contraindications. They explain whether they're prescribing on-label or off-label and why.
This isn't just about what's available. Tirzepatide (GLP-1 + GIP dual agonist) shows greater average weight loss in trial data but isn't appropriate for everyone. Some patients tolerate semaglutide better; some have specific metabolic profiles where tirzepatide's dual mechanism offers more benefit. The choice should be individualized, not just "whatever we have in stock."
Your provider explains the clinical rationale for their recommendation based on your specific metabolic status, weight loss goals, diabetes status, and any relevant history. They acknowledge the option you're not being prescribed and explain why the other choice is preferred for you.
Standard titration schedules exist (see our dosing guide), but your provider should be able to explain exactly what dose you'll start at, when you'll increase, and under what circumstances they'd slow down or pause titration. Knowing the plan in advance helps you manage expectations and recognize when something is off-plan.
You receive a clear written titration schedule, an explanation of why you're starting at that dose, and a description of the criteria for moving to the next dose level (typically 4 weeks of tolerance at current dose).
The best telehealth GLP-1 providers give you real physician access — not just a prescription and a shipping label.
Nausea, vomiting, constipation, and fatigue are the most common GLP-1 side effects — especially during dose increases. You want to know: What should you do if side effects become severe? Can you pause titration? Can you drop back to a lower dose? Is there a 24-hour nurse line or messaging portal? What symptoms would warrant stopping the medication entirely and calling emergency services?
Your provider gives specific guidance on managing common side effects (dietary adjustments, timing changes), explains the titration flexibility available to you, provides a contact method for side effect questions, and lists red-flag symptoms (severe abdominal pain, vision changes, signs of pancreatitis) that warrant immediate medical attention.
In March 2026, most telehealth GLP-1 prescriptions are filled by compounding pharmacies. This is legal and common. But you should know: Is the compounding pharmacy 503A or 503B? Is it PCAB-accredited? What's in the formulation — pure semaglutide/tirzepatide, or a combination with additives like B12? What's the sourcing of the API (active pharmaceutical ingredient)?
You receive the name of the compounding pharmacy, its accreditation status, and details on the formulation. A good provider is transparent about exactly what's in what you're injecting.
This is one of the most important — and least-discussed — questions in GLP-1 therapy. Clinical trial data consistently shows that the majority of patients regain weight when GLP-1 medications are stopped. This is not a failure of willpower; it's the biological reality that these drugs treat a chronic condition (obesity). The conversation should be about long-term maintenance, not just "getting to your goal weight."
An honest provider explains that for most patients, GLP-1 therapy is a long-term maintenance medication — similar to blood pressure or cholesterol medication. They should discuss strategies for eventual dose reduction or discontinuation for appropriate patients, and acknowledge the weight regain data honestly.
GLP-1 therapy doesn't require intensive lab monitoring for most patients, but some baseline and ongoing labs are appropriate — especially if you have diabetes, kidney disease, or are at risk for thyroid issues. Typical baseline labs include comprehensive metabolic panel (CMP), lipid panel, HbA1c (if diabetic or pre-diabetic), and thyroid-stimulating hormone (TSH).
Your provider specifies which labs they recommend before starting, which are optional, and what monitoring interval is appropriate during therapy based on your health status. They explain what lab findings would affect your treatment plan.
Brand-name GLP-1s for weight management remain poorly covered by most commercial insurance plans in the US as of early 2026 — the situation is improving but still challenging. Compounded options are typically cash-pay and not covered by insurance. Knowing your actual out-of-pocket cost upfront prevents surprises.
Your provider or their staff gives you a realistic picture of insurance coverage based on your specific plan, explains the compounded vs. brand-name cost differential, and provides clear monthly cost estimates for the specific formulation they're prescribing.
Helimeds offers transparent pricing on compounded semaglutide and tirzepatide — no surprises.
See Helimeds Pricing →Life happens — surgery, pregnancy planning, financial constraints, illness. Knowing the protocol for pausing and restarting GLP-1 therapy is important. The key question is: how long a pause requires restarting the titration from scratch versus resuming at your last dose?
Your provider explains that pauses under 2–3 weeks typically allow resuming at the previous dose; longer pauses may require dropping back a dose level or restarting titration. They give you a specific protocol for your situation rather than a vague answer.
Beyond the scale, what metrics matter? For metabolic health, the more important numbers are often HbA1c, blood pressure, lipid panel, and waist circumference rather than body weight alone. Weight loss is also dose-dependent and time-dependent — what does the expected trajectory look like for your starting point, and when is it reasonable to reassess?
Your provider sets realistic expectations: meaningful weight loss often begins at 8–12 weeks at therapeutic doses; 5% body weight loss at 3–4 months is a reasonable interim benchmark at mid-titration. They explain which non-scale outcomes to track and at what interval they'd reassess if you're not responding.
This question is underrated. What happens after you reach your goal weight? Can you reduce to a maintenance dose? Is there a dose-tapering protocol, or is it a hard stop? What lifestyle foundation (nutrition, exercise, behavior change) needs to be in place for a discontinuation attempt to have the best chance of success?
Your provider acknowledges the weight regain literature honestly, describes micro-dose or gradual taper options for appropriate candidates, and explains that a supervised transition — not abrupt discontinuation — is the recommended approach for patients who want to stop therapy.
GLP-1 therapy works best when combined with appropriate lifestyle support. Protein intake and resistance training significantly reduce the muscle loss risk associated with rapid weight loss. Behavioral support (nutrition counseling, peer support) improves adherence and outcomes. Some providers also add supplements (B12, magnesium) to support common micronutrient gaps during weight loss. Are any of these relevant to you?
Your provider gives specific guidance based on your age, starting weight, and health status — not just generic "eat well and exercise" advice. They address protein intake targets (typically 1.2–1.6g/kg body weight per day), exercise recommendations, and any supplements appropriate for your situation.
No checklist can replace a good doctor-patient relationship. But arriving prepared with clear questions demonstrates that you're an engaged patient — and engaged patients get better care. Research consistently shows that informed patients have better adherence, better outcomes, and better ability to navigate complications when they arise.
If a provider rushes through your intake without addressing these areas, or seems annoyed that you're asking questions, that's important information about how they'll manage your care going forward. You deserve a provider who sees you as a partner, not a transaction.
The telehealth model that dominates compounded GLP-1 access in March 2026 varies enormously in quality. The best providers offer real physician access, detailed intake evaluations, and ongoing clinical support. Use these questions as a benchmark for evaluating who you're working with — and whether they're worthy of your trust.
GLP-1CompoundPharmacy.com content is produced by a research team with backgrounds in health journalism, clinical pharmacology, and patient advocacy. All clinical claims are sourced from peer-reviewed literature, FDA documents, or named clinical trials. We do not accept payment for editorial coverage. No Fluff. Just Sources.
Providers that answer your questions